Government ❯ Health ❯ Healthcare

Pharmaceuticals

Drug Regulation Drug Safety Prescription Medications Drug Pricing Medication Supply Advertising Drug Advertising Drug Procurement Drug Manufacturing Risk Management Prescription Drugs Regulatory Affairs FDA Drug Approval Medication Delivery Home Delivery Services Supplier Compliance Regulatory Programs Drug Approval Process Export Targets Drug Testing Oncology Medications 340B Program Procurement Processes International Trade Drug Review Process Pharmacy Regulations Regulatory Agencies Quality Control Supply Chain Issues Clinical Trials Manufacturing in Mexico Mifepristone Children's Medicine Pharmaceutical Advertising Regulatory Oversight Medication Pricing Contract Compliance Adverse Effects Debt Management Public Health Application Process Insulin Rejection Process Medicine Supply Drug Quality Cannabis Marketing Authorization Naming Medicines Fees and Payments Illegal Products Medical Representatives Hospital Pharmacy

FDA Escalates Crackdown on Drug Ads, Moves to Close ‘Adequate Provision’ Loophole

The action follows a White House directive, signaling a return to fuller on‑air risk disclosures.

FDA Sends Mass Warnings, Seeks to End 1997 Drug Ad Rule After White House Directive

FDA Launches PreCheck to Accelerate Domestic Drug Plants

HHS Opens Applications for 340B Rebate Model Pilot

FDA Publishes Over 200 Complete Response Letters for 2020–24 Drug Applications